Sanofi gets EU OK for Treatment of Adults With Type 1 Diabetes

The European Commission has granted marketing authorization for Zynquista (sotagliflozin)*, developed by Sanofi and Lexicon (Nasdaq: LXRX). Zynquista is now approved in the European Union, at once-daily doses of 200 mg and 400 mg, for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes (T1D) mellitus and a body mass index 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy.

Millions of people across Europe who live with type 1 diabetes struggle to control their blood sugar, even with optimal insulin therapy, commented Thomas Danne, Professor of Pediatrics, Childrens Hospital Auf der Bult, Hannover, Germany. For the many people living with type 1 diabetes who are overweight or obese, Zynquista will offer a new treatment option physicians can now consider in combination with insulin therapy for appropriate patients.

Zynquista is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-dependent glucose co-transporter types 1 and 2 (SGLT1 and SGLT2).1 SGLT1 is responsible for glucose absorption in the gastrointestinal tract,2 and SGLT2 is responsible for glucose reabsorption by the kidney.

https://www.marketscreener.com/SANOFI-4698/news/Sanofi-Zynquista-now-Approved-in-the-European-Union-for-Treatment-of-Adults-With-Type-1-Diabetes-28494792/